*Applications will be reviewed on a rolling-basis.
A research opportunity is currently available with the Office of Vaccines Research and Reviews (OVRR), at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) located in Silver Spring, Maryland.
This research project will study the mechanisms responsible for the ablated vaccine responses in during neonatal period. The project will involve the cellular and molecular characterization of innate cells and lymphocytes during vaccine responses. The overarching goal of this project is to improve childhood vaccines by modulating molecular and cellular targets unique to neonates with adjuvants. Under the guidance of a mentor, the participant will have a chance to learn and conduct the following experiments: Flow cytometry analysis of lymphoid and bone marrow cells. Flow cytometry will also be used to sort cells from lymphoid organs. Additional cell purification techniques will include isolation of cells with magnetic beads. Sorted cells will be further studied in various ways. These include cultivation under a variety of stimulation conditions, analysis for signaling molecules in Western blot and flow cytometry assays, and gene expression analysis using real-time PCR or RNA-seq techniques. The participant will also learn and perform knock-out mouse breeding and experimentation on neonatal mice. Also, the participant will have a chance to present his/her findings in international scientific meetings.
Anticipated Appointment Start Date: July 1, 2020
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
The qualified candidate should have received a doctoral degree in one of the relevant fields, or be currently pursuing the degree and will reach completion by the appointment start date. Degree must have been received within five years of the appointment start date.
If you have questions, send an email to ORISE.FDA.CBER@orau.org. Please include the reference code for this opportunity (FDA-CBER-2020-0033) in your email.